Literature DB >> 19765454

Genitourinary tumor following kidney transplantation: a multicenter study.

B Einollahi1, N Simforoosh, M Lessan-Pezeshki, A Basiri, M Nafar, F Pour-Reza Gholi, A Firouzan, P Ahmadpour, K Makhdomi, A Ghafari, A Taghizadeh, H Tayebi Khosroshahi.   

Abstract

Renal transplantation has been advocated as the treatment of choice for end-stage renal disease. Immunosuppression increases the incidence of cancer and promotes the growth of neoplasms in solid organ recipients. There have been a few reports on the incidence of cancer from transplant registries. It is difficult to precisely compare the incidence with that in the general population using data from small, single-center studies. Thus, we sought to study the prevalence of genitourinary cancer development in Iranian renal transplant recipients. We collected data from 5 kidney transplant centers in Iran between 1984 and 2008, seeking to detect the incidence, type, and outcome of cancers after kidney transplantation. Only histologically confirmed tumors, which occurred after renal transplantation, were included in the analysis. Of the 5532 patients who underwent kidney transplantation, genitourinary tumors were detected in 21 subjects (0.38%), namely, 12 males and 9 females. Transitional cell carcinoma (TCC) of the bladder, the most common genitourinary cancer (n = 7) was followed by renal cell carcinoma (RCC; n = 5), ovarian cancer (n = 3), breast cancer (n = 3), prostate cancer (n = 1), seminoma (n = 1), and uterine cancer (n = 1). The overall mean age of the patients was 46 +/- 12 years (range, 19-72 years) and the median time to diagnosis after transplantation was 72 months (range, 4-240 months). Seven patients died during the follow-up. There was a male predominance among TCC of the bladder and RCC (5:2 and 4:1, respectively). In conclusion, TCC of the bladder was the most common genitourinary tumor following kidney transplantation. It was predominant in male patients.

Entities:  

Mesh:

Year:  2009        PMID: 19765454     DOI: 10.1016/j.transproceed.2009.07.056

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Total urinary tract exenteration including donor nephrectomy for transitional cell carcinoma 41 years following transplantation.

Authors:  Michael S Floyd; Altaf Q Khattak
Journal:  Int Urol Nephrol       Date:  2014-11-06       Impact factor: 2.370

2.  Are acquired cystic kidney disease and autosomal dominant polycystic kidney disease risk factors for renal cell carcinoma in kidney transplant patients?

Authors:  Behzad Einollahi
Journal:  J Nephropathol       Date:  2012-07-01

Review 3.  De Novo Malignancies after Kidney Transplantation.

Authors:  David Al-Adra; Talal Al-Qaoud; Kevin Fowler; Germaine Wong
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-29       Impact factor: 8.237

Review 4.  Urological Cancers and Kidney Transplantation: a Literature Review.

Authors:  Cristian Axel Hernández-Gaytán; Francisco Rodríguez-Covarrubias; Ricardo A Castillejos-Molina; Andrés Hernández-Porras; Ignacio Tobia; Justin M Dubin; Ana María Autrán-Gómez
Journal:  Curr Urol Rep       Date:  2021-12-16       Impact factor: 3.092

5.  Evidence of BK Polyomavirus Infection in Urothelial but not Renal Tumors from a Single Center Cohort of Kidney Transplant Recipients.

Authors:  Cinzia Borgogna; Silvia Albertini; Licia Martuscelli; Filippo Poletti; Alessandro Volpe; Guido Merlotti; Vicenzo Cantaluppi; Renzo Boldorini; Marisa Gariglio
Journal:  Viruses       Date:  2021-01-03       Impact factor: 5.048

Review 6.  Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review.

Authors:  Dag Olav Dahle; Morten Skauby; Carl Wilhelm Langberg; Knut Brabrand; Nicolai Wessel; Karsten Midtvedt
Journal:  Transplantation       Date:  2022-01-01       Impact factor: 5.385

Review 7.  Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge.

Authors:  Li-Jen Wang; Shen-Yang Lee; Bin Tean Teh; Cheng-Keng Chuang; Joëlle Nortier
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.